In this Healio Video Perspective from the ASCRS meeting, Brandon D. Ayres, MD, discusses the effectiveness and safety of a 27 ...

Deaths attributed to both acute heart attack and obesity rose between 2007 and 2019, according to findings from the CDC ...

Fewer patients with autoimmune disease are dying due to cardiovascular disease, but women remain at higher risk vs. men, ...

Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental ...

Nutrition is critical for combating chronic diseases in the United States, but research on optimal diets is inconsistent, ...

Dermatology patients living in the most disadvantaged neighborhoods were three times more likely to receive a diagnosis of ...

Heightened exposure levels to particulate matter before COVID-19 hospitalization raised the odds for poor outcomes in ...

Researchers projected CT use in 2023 would lead to more than 100,000 future cancer diagnoses, and if trends continued, may ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with Crohn’s disease, offering both IV and subcutaneous induction options.

Careful examination of clinical trial data and a better understanding of risk factors can help rheumatologists determine if a ...

In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

In this video, Ursula A. Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer.Findings from a phase 1/2a study of ...